{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:49:44Z","timestamp":1791575384379,"version":"4.3.4"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Cancer therapy-induced thrombocytopenia (CTIT) is a common complication in patients with lung cancer undergoing treatment, leading to treatment delays and dose reductions. Romiplostim N01, a thrombopoietin receptor agonist, has shown potential in managing severe persistent CTIT. This study aims to describe platelet recovery outcomes and safety associated with Romiplostim N01 for managing severe persistent CTIT in patients with lung cancer, providing real-world clinical evidence. This single-center observational study enrolled 56 patients with lung cancer who developed severe persistent CTIT and received Romiplostim N01 treatment from June 1, 2024, to February 28, 2025. Data on clinical characteristics, prior treatments, CTIT severity, and platelet recovery outcomes were retrospectively collected and analyzed. The primary endpoints were platelet recovery rates and the safety profile of Romiplostim N01. Of the 56 patients, 89.3% achieved platelet recovery to \u2265100\u2005\u00d7\u200510\n                      <jats:sup>9<\/jats:sup>\n                      \/L, with a median recovery time of 16 days (range: 3\u201363 days). The treatment was well tolerated, with no serious adverse events. The most common adverse event was joint pain (10.7%), and thrombocytosis occurred in 26.8% of patients. No significant drug interactions or severe complications were observed. Additionally, patients received concomitant supportive therapies, such as platelet transfusions or oral thrombopoietin receptor agonists. Romiplostim N01 was associated with favorable platelet recovery proportions and a manageable safety profile in patients with lung cancer and severe persistent CTIT. These findings suggest that Romiplostim N01 is a viable option for managing severe persistent CTIT, though further large-scale, multicenter studies are needed to validate its platelet recovery outcomes and safety across diverse patient populations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000051010","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:00:44Z","timestamp":1791572444000},"page":"e51010","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Single-center experience with Romiplostim N01 for the management of severe persistent cancer therapy-induced thrombocytopenia in lung cancer"],"prefix":"10.1097","volume":"105","author":[{"given":"Changjian","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangyan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijiang","family":"Fei","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zong","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Dong","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4491-4811","authenticated-orcid":false,"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/cam4.856","article-title":"Partial splenic embolization to permit continuation of systemic chemotherapy.","volume":"5","author":"Luz","year":"2016","journal-title":"Cancer Med"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia.","volume":"14","author":"Al-Samkari","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12885-019-5354-5","article-title":"Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice.","volume":"19","author":"Weycker","year":"2019","journal-title":"BMC Cancer"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1111\/1759-7714.13683","article-title":"Genetic variants as predictors of toxicity and response in patients with non-small cell lung cancer undergoing first-line platinum-based chemotherapy: design of the multicenter PGxLUNG study.","volume":"11","author":"de Jong","year":"2020","journal-title":"Thorac Cancer"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/ejh.13595","article-title":"The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies.","volume":"106","author":"Shaw","year":"2021","journal-title":"Eur J Haematol"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 family proteins are essential for platelet survival.","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell Death Differ"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"key":"R10-20261009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists.","volume":"98","author":"Kuter","year":"2013","journal-title":"Int J Hematol"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia.","volume":"37","author":"Soff","year":"2019","journal-title":"J Clin Oncol"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"e7429","DOI":"10.1002\/cam4.7429","article-title":"Romiplostim in chemotherapy-induced thrombocytopenia: a review of the literature.","volume":"13","author":"Soff","year":"2024","journal-title":"Cancer Med"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"e12701","DOI":"10.1002\/rth2.12701","article-title":"Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use.","volume":"6","author":"Wilkins","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"R15-20261009","doi-asserted-by":"crossref","first-page":"1634688","DOI":"10.3389\/fimmu.2025.1634688","article-title":"Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management.","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/bjh.20037","article-title":"Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment.","volume":"206","author":"Song","year":"2025","journal-title":"Br J Haematol"},{"key":"R17-20261009","first-page":"925","article-title":"Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.","volume":"28","author":"Crawford","year":"2020","journal-title":"Support Care Cancer"},{"key":"R18-20261009","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","article-title":"Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer.","volume":"18","author":"Denduluri","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"R19-20261009","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","article-title":"A review of relative dose intensity and survival in patients with metastatic solid tumors.","volume":"93","author":"Havrilesky","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"R20-20261009","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.2001.19.4.1137","article-title":"Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia.","volume":"19","author":"Elting","year":"2001","journal-title":"J Clin Oncol"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00063030-199810020-00006","article-title":"Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia.","volume":"10","author":"Wilde","year":"1998","journal-title":"BioDrugs"},{"key":"R22-20261009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0037-1963(00)90050-7","article-title":"Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia.","volume":"37","author":"Vadhan-Raj","year":"2000","journal-title":"Semin Hematol"},{"key":"R23-20261009","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2006-10-019315","article-title":"New thrombopoietic growth factors.","volume":"109","author":"Kuter","year":"2007","journal-title":"Blood"},{"key":"R24-20261009","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1002\/cncr.11447","article-title":"Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy.","volume":"97","author":"Cantor","year":"2003","journal-title":"Cancer"},{"key":"R25-20261009","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann Intern Med"},{"key":"R26-20261009","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-003-0737-7","article-title":"Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia\u2013a randomized, placebo-controlled, double-blind safety and efficacy study.","volume":"82","author":"Geissler","year":"2003","journal-title":"Ann Hematol"},{"key":"R27-20261009","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","article-title":"Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.","volume":"99","author":"Basser","year":"2002","journal-title":"Blood"},{"key":"R28-20261009","doi-asserted-by":"crossref","first-page":"2040620719841735","DOI":"10.1177\/2040620719841735","article-title":"Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.","volume":"10","author":"Al-Samkari","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"R29-20261009","doi-asserted-by":"crossref","first-page":"2040620720912992","DOI":"10.1177\/2040620720912992","article-title":"The role of romiplostim for pediatric patients with immune thrombocytopenia.","volume":"11","author":"Al-Samkari","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"R30-20261009","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia.","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"key":"R31-20261009","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bja.2018.09.010","article-title":"Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies.","volume":"122","author":"Nagrebetsky","year":"2019","journal-title":"Br J Anaesth"},{"key":"R32-20261009","doi-asserted-by":"crossref","first-page":"e0257673","DOI":"10.1371\/journal.pone.0257673","article-title":"Systematic literature review and meta-analysis on use of thrombopoietic agents for chemotherapy-induced thrombocytopenia.","volume":"17","author":"Soff","year":"2022","journal-title":"PLoS One"},{"key":"R33-20261009","doi-asserted-by":"crossref","first-page":"17588359241260985","DOI":"10.1177\/17588359241260985","article-title":"Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study.","volume":"16","author":"Qin","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"R34-20261009","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/bjh.17872","article-title":"Novel therapies for immune thrombocytopenia.","volume":"196","author":"Kuter","year":"2022","journal-title":"Br J Haematol"},{"key":"R35-20261009","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18413\/rrpharmacology.9.10011","article-title":"Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia.","volume":"9","author":"Levchenkova","year":"2023","journal-title":"Res Results Pharmacol"},{"key":"R36-20261009","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/DDDT.S299591","article-title":"A review of romiplostim mechanism of action and clinical applicability.","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"R37-20261009","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/bjh.16658","article-title":"Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry.","volume":"190","author":"Mytych","year":"2020","journal-title":"Br J Haematol"},{"key":"R38-20261009","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","article-title":"Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand.","volume":"76","author":"Wang","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R39-20261009","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.","volume":"161","author":"Kuter","year":"2013","journal-title":"Br J Haematol"},{"key":"R41-20261009","doi-asserted-by":"crossref","first-page":"704093","DOI":"10.3389\/fphar.2021.704093","article-title":"Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trial.","volume":"12","author":"Deng","year":"2021","journal-title":"Front Pharmacol"},{"key":"R42-20261009","first-page":"535","article-title":"Chinese expert consensus on the clinical application of recombinant human thrombopoiein and thrombopoiein receptor agonist (2023).","volume":"44","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R43-20261009","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ajh.24935","article-title":"Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers.","volume":"93","author":"Cantoni","year":"2018","journal-title":"Am J Hematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000051010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:00:49Z","timestamp":1791572449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000051010"}},"subtitle":["Insights and outcomes"],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":41,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000051010","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"2025-10-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}